Abaloparatide与骨盆骨折愈合:一项2期随机安慰剂对照试验
在48例急性骨盆骨折患者中,评估Abaloparatide(ABL)与安慰剂(PBO)相比是否改善3个月时的愈合。结果显示,两组在CT影像学愈合、身体性能和疼痛变化方面均无显著差异。
要点
- 3个月时ABL组与PBO组皮质桥接评分分布无显著差异(p=0.15)。
- ABL组愈合率39%,PBO组64%(RR 0.61;95%CI 0.33,1.12)。
- 功能测试(SPPB、TUG)两组随时间改善但无组间差异。
核心结论
- 在急性骨盆骨折患者中,ABL与安慰剂相比在CT影像学愈合、身体性能和疼痛变化方面无显著差异。
研究设计与样本
- 2期随机、双盲、安慰剂对照试验,纳入48例绝经后女性和≥50岁男性骨盆骨折患者,骨折后4周内入组。
主要发现
- 3个月CT影像桥接评分分布两组无显著差异(p=0.15),校正年龄、骶骨骨折、移位或依从性后仍无差异。
- 单个骨折(n=81)桥接评分两组相似(p=0.13)。
- 患者水平愈合率ABL组39% vs PBO组64%(RR 0.61;95%CI 0.33,1.12)。
- 单个骨折水平愈合率ABL组47% vs PBO组53%(RR 0.88;95%CI 0.55,1.40)。
- 基线NRS疼痛评分安慰剂组高于ABL组(p<0.05),但疼痛评分变化、SPPB和TUG评分两组无组间差异。
关键数值与推荐
- 主要终点为3个月骨折愈合,由两名放射科医生使用5点量表评估CT皮质桥接,采用Jonckheere-Terpstra检验比较组间。
- 愈合定义为3或4个皮质桥接,采用Mantel-Haenszel相对风险(RR)分析。
临床怎么用
- 当前证据不支持使用Abaloparatide促进急性骨盆骨折的影像学愈合或改善功能结局。
局限性
- 样本量小(n=48),可能不足以检测组间差异。
- 研究为2期试验,随访仅3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Pelvic fractures result in prolonged pain and immobility. In a randomized controlled trial of patients with pelvic fracture, whether abaloparatide (ABL) vs. placebo (PBO) improves healing at 3 months was evaluated. There was no significant difference in CT radiologic healing, physical performance, or change in pain in ABL vs. placebo. PURPOSE: To determine if abaloparatide (ABL) vs. placebo (PBO) improves radiologic healing, pain, and functional outcome at 3 months in patients with pelvic fracture. METHODS: Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO. The primary endpoint, fracture healing at 3 months, was assessed by two radiologists using a 5-point scale for cortical bridging from CT images comparing groups by Jonckheere-Terpstra test. The odds of healing (3 or 4 cortices bridged) were analyzed with Mantel-Haenszel relative risks (RR). Pain was assessed monthly by Numeric Rating Scale (NRS). The Short Physical Performance Battery (SPPB; walk speed, chair stands, and balance) evaluated functional mobility. RESULTS: Groups were balanced with a mean age = 82, 93% were female, 98% had multiple rami fractures, 67% had sacral fracture, and 36% had ≥ 1 displaced fracture. CT images at 3 months showed no significant difference in bridging score distribution (indicator of healing) in patients with ABL vs. PBO (p = 0.15) after adjusting for age, sacral fracture, displacement, or compliance. When evaluating individual fractures (n = 81), similar bridging scores were seen with ABL and PBO (p = 0.13). When patients were stratified as healed or not healed, 39% were healed with ABL and 64% healed with PBO (RR 0.61; 95% CI 0.33, 1.12). When looking at the 81 individual fractures, 47% were healed with ABL and 53% healed with PBO (RR = 0.88; 95% CI 0.55, 1.40). Using least square means controlling for age, sacral, and displaced fracture, NRS pain score was higher in the placebo than the ABL group at baseline (p < 0.05), but there were no further group differences in change in pain score SPPB and TUG scores improved over time in both groups without group differences. CONCLUSION: In this small study, there was no significant difference in CT radiologic healing, physical performance, or change in pain with ABL vs. placebo in patients with acute pelvic fracture. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04249232 registered January 27, 2020.
引用
- Nieves JW, Cosman F, McMahon D, et al. Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial. Osteoporos Int. 2026. PMID: 42618812. doi:10.1007/s00198-026-08176-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。